Clinical Trial

SLV-154 Treatment of Advanced Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Protocol Amendment History 5 changes
critical Primary endpoint(s) modified 2026-07-25
notable Enrollment increased: 70 -> 250 participants 2026-07-25
minor Trial arms changed: 8 -> 6 2026-07-25
notable Primary completion pushed: 2027-01 -> 2027-08 2026-07-25
minor Completion pushed: 2027-04 -> 2027-11 2026-07-25
Trial Details
NCT Number NCT06771219
Lead Sponsor Solve Therapeutics
Conditions Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Enrollment 250 participants
Start Date 2025-05-14
Primary Completion 2027-08 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-24